Cargando…
Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome. ARQ 092 is an allosteric pan-AKT inhibitor under development for treatment in cancer. We tested the e...
Autores principales: | Lindhurst, Marjorie J., Yourick, Miranda R., Yu, Yi, Savage, Ronald E., Ferrari, Dora, Biesecker, Leslie G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675973/ https://www.ncbi.nlm.nih.gov/pubmed/26657992 http://dx.doi.org/10.1038/srep17162 |
Ejemplares similares
-
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
por: Biesecker, Leslie G., et al.
Publicado: (2020) -
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015) -
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
por: Nandan, Devki, et al.
Publicado: (2018) -
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017)